{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-073991","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2025-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.284882+00:00","generated_at":"2026-05-23T19:33:45.876722+00:00","sec_items":["2.01","2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zevra closes $150M sale of rare pediatric disease PRV, boosting cash to ~$217M","bullets":["Closed sale of Rare Pediatric Disease Priority Review Voucher for $150M gross proceeds on April 1, 2025.","PRV granted by FDA in Sept 2024 following approval of MIPLYFFA for Niemann-Pick disease type C.","Unaudited cash, cash equivalents and investments at Mar 31, 2025 were $68.7M.","Pro forma cash after net proceeds of $148.3M is $217M; CFO cites support for MIPLYFFA and OLPRUVA launches and celiprolol Phase 3 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-073991","json":"https://secwatch.observer/filing/0001193125-25-073991.json","markdown":"https://secwatch.observer/filing/0001193125-25-073991.md","text":"https://secwatch.observer/filing/0001193125-25-073991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000119312525073991/0001193125-25-073991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000119312525073991/d938703d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:33:45.876722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}